Collard A. Craig's Insider Trades & SAST Disclosures
Collard A. Craig's most recent trade in Heron Therapeutics Inc was a trade of 34,789 Common Stock done . Disclosure was reported to the exchange on April 30, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Collard A. Craig.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Heron Therapeutics Inc | A. Craig Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 34,789 | 425,952 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Collard A. Craig | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 34,789 | 521,831 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2025 | 13,796 | 391,163 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2025 | 13,796 | 151,766 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2025 | 62,500 | 377,367 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2025 | 62,500 | 125,000 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 1,113,240 | 1,113,240 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 556,620 | 556,620 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 13,797 | 314,867 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 13,797 | 165,562 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 13,797 | 290,387 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 13,797 | 179,359 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 13,797 | 193,156 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 13,797 | 276,590 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 13,797 | 262,793 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 13,797 | 206,953 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 62,500 | 248,996 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 62,500 | 187,500 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | A. Craig Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 1,324,502 | 1,324,502 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 220,750 | 220,750 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.65 per share. | 22 Aug 2023 | 692 | 36,496 (0%) | 0% | 1.7 | 1,142 | Common Stock |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.45 per share. | 22 May 2023 | 691 | 37,188 (0%) | 0% | 1.5 | 1,002 | Common Stock |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 4,250,000 | 4,250,000 | - | - | Employee Performance Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 3,000,000 | 3,000,000 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 250,000 | 250,000 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges